Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 4399Urinary Bladder Neoplasms 1078Carcinoma, Renal Cell 1041Kidney Neoplasms 567Breast Neoplasms 453Neoplasms 403Carcinoma, Transitional Cell 299Neoplasm Metastasis 250Lung Neoplasms 242Testicular Neoplasms 202Melanoma 195Colorectal Neoplasms 193Ovarian Neoplasms 163Carcinoma, Non-Small-Cell Lung 150Sarcoma 135Non-Muscle Invasive Bladder Neoplasms 135Pancreatic Neoplasms 124Colonic Neoplasms 121Head and Neck Neoplasms 116Uterine Cervical Neoplasms 115Wilms Tumor 108Recurrence 106Motor Activity 100Stomach Neoplasms 89Urologic Neoplasms 88Neuroblastoma 88Disease 85Multiple Myeloma 83Carcinoma, Hepatocellular 79Adenocarcinoma 79

Interventions

Radiosurgery 1Deamino Arginine Vasopressin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Castrate Resistance Prostate Cancer × Genitourinary × Clear all
NCT06927635 2025-09-05

SECURE

University Health Network, Toronto

Phase 2 Recruiting
75 enrolled
Genitourinary

Castrate Resistance Prostate Cancer

NCT04113005 2019-10-02

Safety and Tolerability Analysis of Combining Desmopressin With Docetaxel for the Treatment of Castration-Resistant Prostate Cancer

Sunnybrook Health Sciences Centre

Phase EARLY_PHASE1 Unknown
10 enrolled
Genitourinary

Castrate Resistance Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡